Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR

使用 IVR 提高对口腔癌药物的依从性和症状的自我护理

• 批准号: 8816052
• 负责人: BARBARA ANN GIVEN
• 金额: $ 61.36万
• 依托单位: MICHIGAN STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8816052
• 关键词: Address; Adherence; Admission activity; Adverse effects; Age; Antineoplastic Agents; Cancer Center; Cancer Patient; Caring; Characteristics; Clinical; Communication; Complex; Comprehensive Cancer Center; Development; Disease; Dose; Emergency department visit; Environmental Risk Factor; Generations; Goals; Health; Hospitals; Infusion procedures; Intervention; Learning; Link; Literature; Malignant Neoplasms; Marketing; Measurement; Mental Depression; Modeling; Monitor; Oncologist; Oral; Outcome; Patient Agents; Patient Self-Report; Patients; Pharmaceutical Preparations; Pharmacists; Physicians; Pilot Projects; Provider; Publishing; Randomized; Records; Regimen; Reminder Systems; Reporting; Research; Self Care; Self Management; Severities; Site; Symptoms; System; Technology; Testing; Time; Toxic effect; Translations; Treatment Protocols; Variant; Visit; Voice; Work; Writing; arm; cancer therapy; chemotherapy; compliance behavior; evidence base; experience; follow-up; improved; malignant mouth neoplasm; multi-site trial; novel; novel strategies; oncology; patient oriented; patient safety; pill; response; satisfaction; sex; symptom management; treatment planning; trial comparing; two-arm study; web site

DESCRIPTION (provided by applicant): The goals of this application are to improve adherence to oral chemotherapeutic medications and self- management of symptoms among cancer patients. Forty oral agents currently are on the market with projections that in 3 years 25% of the cancer treatment agents will be delivered in oral form. As a result, patients must assume responsibility for taking medications and self-management of associated side effects. To address these issues we collaborate with four NCI Comprehensive Cancer Centers who will identify patients as they are prescribed oral agents, present the study, and those accepting will be randomized to one of two arms. All patients in both arms will receive 8 weekly assessments of adherence and symptom severity. In addition, those in the experimental arm will receive daily reminder calls for the initial 4 weeks of their scripts tailored to their dose. For symptoms reported above threshold they will be referred to a symptom management guide (SMG) to assist with self-management. A unique feature is that assessments, reminders, and symptom management strategies will be delivered by an Interactive Voice Response system (IVR). This system has been tested in a previous trial and in a pilot study of adherence; it received high satisfaction ratings from patients. The following outcomes are tested: at 4 weeks the experimental arm will have higher levels of self-reported adherence, and symptom management and these differences will be sustained at 8 and at 12 weeks. In addition, the experimental arm will report lower rates of both over and under adherence at 4, 8, and 12 weeks. Exploratory aims assess the moderating effects patient and treatment variables on adherence and symptom management. A final exploratory aim evaluates an important but heretofore untested question: what is the relationship between adherence and patients' symptom management? This research is guided by past trials and a large pilot study of adherence to oral agents and symptom management. Patient reported adherence is validated against pill counts, and scripts from patients' records. Daily reminders include a question to determine if dose was changed. If this occurs, staff in each site monitor visits and calls so that reminders are stopped or adjusted to dose immediately upon any alteration. All strategies for managing symptoms are evidence based and tested through earlier work of this team. Symptoms reaching urgent levels are communicated to staff at each site. This trial is coordinated through a project website. The impact of this trial is that it tests a short targeted reminder system to model adherence at the onset of treatment. It is accompanied by patient centered strategies for symptom management. This system is embedded into oncology centers; it can potentially transform oral chemotherapy treatment while assuring patient safety.

描述（由申请人提供）：本申请的目的是提高癌症患者对口服化疗药物的依从性和对症状的自我管理。目前市场上有40种口服药物，预计3年内25%的癌症治疗药物将以口服形式提供。因此，患者必须承担服药和自我管理相关副作用的责任。为了解决这些问题，我们与四个NCI综合癌症中心合作，他们将识别患者，并给他们开口服药物，进行研究，接受治疗的患者将随机分为两组之一。两组的所有患者将接受每周8次的依从性和症状严重程度评估。此外，实验组的患者将在最初4周收到根据剂量量身定制的处方的每日提醒电话。对于报告的高于阈值的症状，将参考症状管理指南（SMG），以帮助进行自我管理。其独特之处在于，评估、提醒和症状管理策略将由交互式语音应答系统（IVR）提供。该系统已在先前的试验和依从性的试点研究中进行了测试；病人对它的满意度很高。对以下结果进行了测试：在第4周时，实验组的自我报告依从性水平较高，症状管理和这些差异将持续到第8周和第12周。此外，在第4周、第8周和第12周，实验组的依从性和依从性均较低。探索性目的评估患者和治疗变量对依从性和症状管理的调节作用。最后一个探索性的目的是评估一个重要的，但迄今尚未测试的问题：依从性和患者症状管理之间的关系是什么？本研究以过去的试验和一项关于口服药物依从性和症状管理的大型试点研究为指导。患者报告的依从性根据药片数量和患者记录中的处方进行验证。每日提醒包括一个问题，以确定剂量是否改变。如果发生这种情况，每个站点的工作人员对访问和电话进行监督，以便在发生任何更改时立即停止提醒或调整剂量。所有管理症状的策略都是基于证据的，并通过该团队早期的工作进行了测试。达到紧急级别的症状将通知每个站点的工作人员。该试验通过一个项目网站进行协调。这项试验的影响在于，它测试了一个短期的有针对性的提醒系统，以模拟治疗开始时的依从性。它伴随着以患者为中心的症状管理策略。这个系统被嵌入肿瘤中心；它有可能在确保患者安全的同时改变口服化疗治疗。